Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium

View Paper Here

Simon Heller, FRCP,  Börje Darpö, MD, PhD,  Malcolm I. Mitchell, MBBS, MFPM, Helle Linnebjerg, PhD, Derek J. Leishman, PhD, DSP,  Nitin Mehrotra, PhD,  Hao Zhu, PhD,  John Koerner, PhD,  Mónica L. Fiszman, MD, PhD,  Suchitra Balakrishnan, MD, PhD,  Shen Xiao, MD, PhD,  Thomas G. Todaro, MD, JD,  Ingrid Hensley, PhD,  Brian D. Guth, PhD,  Eric L. Michelson, MD, FACC, and Philip Sager, MD, FACC, FAHA, FHRS  Sheffield,United Kingdom; Stockholm, Sweden; Rochester, NY; Indianapolis, IN; Silver Spring, MD; Cincinnati, OH; Biberach an der Riss, Germany; Philadelphia, PA; and Stanford, CA

Comparison of Quality-of-Life Measures after Radial versus Femoral Artery Access for Cardiac Catheterization in Women: Results of the SAFE-PCI for Women Quality-of-Life Substudy

View Paper Here

Connie N. Hess, MD, MHSa; Mitchell W. Krucoff, MDa; Shubin Sheng, MSa; Kevin J. Anstrom, PhDa; W. Britt Barham, BAa; Ian C. Gilchrist, MDb; Robert A. Harrington, MDc; Alice K. Jacobs, MDd; Roxana Mehran, MDe; John C. Messenger, MDf; Daniel B. Mark, MDa; Sunil V. Rao, MDa; aDuke Clinical Research Institute, Durham, NC; bHeart & Vascular Institute, Pennsylvania State University, College of Medicine, Hershey, PA; cDepartment of Medicine, Stanford University, Stanford, CA; dDepartment of Medicine, Boston University School of Medicine, Boston, MA; eCardiovascular Research Foundation, Mount Sinai Medical Center, New York, NY; fDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO

Novel oral anticoagulants and reversal agents: Considerations for clinical development

View Paper Here

Troy C. Sarich, PhD, a Jonathan H. Seltzer,MD, b Scott D. Berkowitz,MD, c James Costin’,MD, d John T. Curnutte,MD, e C. Michael Gibson, MD, f Maureane Hoffman, MD, PhD, g Edvardas Kaminskas, MD, h Mitchell W. Krucoff, MD, i Jerrold H. Levy, MD, j Paul D. Mintz, MD, k Paul A. Reilly, PhD, l Philip T. Sager, MD, m Daniel E. Singer, MD, n Norman Stockbridge, MD, PhD, o Jeffrey I. Weitz, DM, p and Peter R. Kowey, MD q Titusville, NJ; Wynnewood, PA; Whippany, NJ; Danbury, CT; South San Francisco, CA; Boston, MA; Durham, NC; Silver Spring, MD; Ridgefield, CT; Hamilton, ON; and Philadelphia, PA

Cardiac Safety Research Consortium: Can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward

American Heart Journal, September 2014

View Paper Here

Borje Darpo, MD, PhD, Christine Garnett, PharmD, Charles T. Benson, MD, PhD, James Keirns, PhD,  Derek Leishman, PhD, f Marek Malik, MD, PhD, Nitin Mehrotra, PhD, Krishna Prasad, MD, FRCP, Steve Riley, PharmD, PhD, Ignacio Rodriguez, MD, Philip Sager, MD, Nenad Sarapa, MD, and Robert Wallis, PhD  Stockholm, Sweden; Rochester, NY; St Louis, MO; Indianapolis, IN; Northbrook, IL; London, United Kingdom; Silver Spring, MD; Groton, CT; New York, NY; Palo Alto, CA; Inc. Whippany, NJ; and Sandwich, United Kingdom

Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium

American Heart Journal, February 2015

View Paper Here

Jonathan H. Seltzer, MD, MBA, MA, a J. Rick Turner, PhD, b Mary Jane Geiger, MD, PhD, c
Giuseppe Rosano, MD, PhD, d Kenneth W. Mahaffey, MD, e William B. White, MD, f Mary Beth Sabol, MD, g Norman Stockbridge, MD, PhD, h and Philip T. Sager, MD i Bala Cynwyd, PA; Durham, NC; Tarrytown, NY; London, UK; Palo Alto, CA; Farmington, CT; Upper Providence, PA; and Silver Spring, MD